WASHINGTON (AP) — Federal regulators are challenging patents on 20 brand name drugs, including the blockbuster weight-loss injection Ozempic, in the latest action by the Biden administration targeting industry practices that drive up pharmaceutical prices.
The Federal Trade Commission on Tuesday sent warning letters to 10 drugmakers, taking issue with patents on popular drugs for weight loss, diabetes, asthma and other reparatory conditions. The letters allege that certain patents filed by Novo Nordisk, GlaxoSmithKline, AstraZeneca and seven other companies are inaccurate or misleading.
Brand-name drugmakers use patents to protect their medicines and stave off cheaper, generic medicines. Most blockbuster drugs are protected by dozens of patents covering various ingredients, manufacturing processes and intellectual property. Generic drugmakers can only launch their own cheaper versions if the patents have expired or are successfully challenged in court.
Related articles:
Related suggestion:
Japan helicopter crash: Flight data show no sign of mechanical failureTerry Anderson, AP reporter abducted in Lebanon and held captive for years, has died at 76China's interbank treasury bond index opens higher FridayChina's top political advisory body starts annual sessionWADA stands by decision to clear Chinese swimmers for Tokyo Olympics citing contaminated samplesOlivia Dunne shares selfie in allTerry Anderson, AP reporter abducted in Lebanon and held captive for years, has died at 76Red Stars win at Reign. Angel City tops Courage for its first home win of the yearAustralian woman appears in court charged with poisoning husband and his relatives with mushroomsChina's Dongfeng NEV brand Voyah makes debut in Italy
3.1428s , 6500.4921875 kb
Copyright © 2024 Powered by US challenges 'bogus' patents on Ozempic and other drugs in effort to spur competition ,Culture Curves news portal